Drug Trial Radar · NCT00060515
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
Last checked: Nov 20, 2026Latest source record: Aug 5, 2005 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
12
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Repligen CorporationIndustry
- Sponsor type
- Industry
- First posted
- May 8, 2003
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
Conditions
- Mitochondrial Diseases
Interventions
RG2133 (2',3',5'-tri-O-acetyluridine)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.